A pharma product’s lifecycle will reach a significant milestone in the form of patent expiry. In an initial drug development phase, the manufacturer may be granted a patent that lasts for 20 years from the patent’s filing date. This protected period enables the innovator company to market the product without direct competition from equivalent generic or biosimilar products. This period helps the company recover research and development costs and establish the product in the market.
Once relevant patent and regulatory protections expire, other companies may be able to develop and market generic or biosimilar versions of the product. These alternatives can increase competition and place downward pressure on prices. Let’s understand the effects of pharmaceutical drug patent expiry and how it affects prices, regulations, and more.
Impact of Drug Patent Expiry on Prices
After the drug patent expires, various trends influence the changes in drug prices:
Generic Competition & Price Reduction
Generic competition entering the market can cause a significant reduction in the prices of treatment. For conventional small-molecule medicines, prices may decline substantially when multiple generic manufacturers enter the market. In other cases, the decline may be more gradual, particularly where only a limited number of manufacturers are able or willing to produce the medicine.
This means every medicine doesn’t reduce the same way. Factors like the number of approved competitors, prescribing patterns, distribution arrangements, reimbursement policies, and the cost of product manufacturing.
The FDA’s Generic Drug Facts explains that generic medicines may be approved after applicable patents and exclusivities have expired or have been successfully challenged.
Branded Drug Price Maintenance
Some brand-name manufacturers maintain higher prices even after their patents expire. It’s a result of strategies like brand loyalty and perception. Patients and physicians stick to the familiar branded drug because of this. Also, when only a few equivalents are available, prices will remain high.
Pharmaceutical companies use “evergreening” tactics, like reformulating drugs or introducing new delivery systems to extend market exclusivity. It keeps prices higher. Further, some companies launch “authorized generics” (generic versions of their own brand-name drugs) at a slightly lower price but not as low as competing generics. It helps them keep market control.
Slower Market Entry for Generics and Biosimilars
Regulatory and legal delays can cause the competitors to enter late into the arena. A generic applicant may receive approval after they address listed patents, patent litigation, exclusivity periods, manufacturing requirements, and regulatory deficiencies. It may also get delayed due to patent infringement lawsuits or additional patents to delay the launch of competing generics. This trend can keep prices higher for longer periods of post-patent expiry.
For biosimilars, development is generally more complex than for conventional generics because biological medicines are structurally complex and are produced using living systems. The scientific and regulatory principles are used for biosimilar marketing authorization in the European Union.
Impact of Biosimilars on Biologics
Biosimilar competition does not always produce the same pricing pattern as generic competition for small-molecule medicines. The price impact varies according to:
- The number of biosimilars approved and marketed
- The complexity of the biological product
- Manufacturing and development costs
- Physician and patient acceptance
- Interchangeability and substitution rules
- Tendering and reimbursement practices
- The strength of competition among manufacturers
Therefore, it is more accurate to say that biosimilars can create meaningful price competition, while the size and speed of price reductions vary by product and market. A fixed estimate, such as a universal 10–30% reduction, should not be applied to all biologics.
Government and Payer Pressure
The government and health insurance providers scrutinize tightly. It calls for reduced prices for branded drugs and their generic counterparts. Medicine expenses may be reduced when governments, public healthcare systems, and private insurers use price negotiations, reimbursement controls, reference pricing, tendering, and formulary management.
Emergence of Competitive International Markets
Patent expiry happens distinctly in every country. Its terms, regulatory exclusivities, approval routes, compulsory licensing rules, reimbursement systems, and substitution policies are different in every area.
Some international markets like India and China introduce generics more quickly. The prices they set are quite lower, resulting in aggressive price competition in these regions.
Increased Focus on Specialty Drugs
Specialty medicines include products used in oncology, rare diseases, and complex chronic conditions. These may retain higher prices even after patent expiry. This can occur because of the following:
- The product is difficult to manufacture
- The dosage form is technically complex
- Few manufacturers have the required capabilities
- The patient population is small
- Distribution and administration are specialized
- Additional patents or regulatory exclusivities remain in force
Therefore, patent expiry may create an opportunity for competition without necessarily producing an immediate or dramatic price reduction.
Fewer Generic Manufacturers
The number of suppliers for a particular medicine may reduce due to the following:
- Consolidation in the generic-drug industry
- Manufacturing interruptions
- Commercial pressures
Competition in fewer manufacturers means prices may not fall as quickly or as significantly as expected. This means that patent expiry alone does not guarantee immediate or sustained price competition. The market must also have enough manufacturing capacity and a reliable supply.
Rising Costs of Generic Drug Development
Generic medicines may not require the same clinical development program as the original product. However, manufacturers may still need to conduct bioequivalence studies, develop suitable manufacturing processes, initiate quality systems, and meet regulatory requirements that apply.
Complex dosage forms, sterile products, modified-release formulations, inhalation products, and other technically challenging medicines can require significant investment. These costs may affect the number of manufacturers that enter the market and the final price of the generic product.
Regulatory Challenges in Bringing Generic Drugs to the Market Post-Patent Expiry
Generic drugs are medicines developed to be equivalent to an already authorized reference product in terms of relevant characteristics such as dosage form, strength, route of administration, quality, and performance. Their inactive ingredients, color, shape, packaging, and name may differ. It’s subject to the applicable regulatory requirements being met.
In the United States, generic drugs are generally approved through an Abbreviated New Drug Application, or ANDA. it is submitted to the US. Food and Drug Administration. This is how applicants can rely on the FDA’s previous findings for the reference drug instead of repeating the full preclinical and clinical development programme.
In the European Union, generic medicines may be assessed by the EMA or by national competent authorities. It depends on the applicable authorization procedure.
Key Features of the Generic Drug Approval Process
The drug approval process for generic medicines looks like the following:
No Requirement to Repeat Clinical Trials
An ANDA generally does not require the applicant to repeat the extensive animal studies and clinical trials for the reference product. Instead, the applicant should prove that the generic satisfies the applicable quality, pharmaceutical equivalence, and bioequivalence requirements.
Bioequivalence Testing
Generic manufacturers generally conduct bioequivalence studies to show that the active ingredient becomes available in the body at a comparable rate. Also, according to the extent of the reference product within the applicable regulatory standards. The study requirements may differ depending on the medicine.
Therapeutic Equivalence
The generic drug should be substituted for the brand-name drug in the sense that they provide the same clinical effect.
Labeling Requirements
The generic drug must have the same labeling as the brand name drug. Any difference that a particular regulatory body permits might cover inactive ingredients, manufacturer of information, packaging, or other legally permitted matters.
Regulatory Challenges for Generic Drugs Before Market Entry
Regulatory challenges also apply before a generic drug enters the market. These include the following:
Patent Certifications
As part of an ANDA, a generic applicant must address patents listed for the reference product in the FDA’s Orange Book. The principal certification categories are as follows:
- Paragraph I: No patent information has been submitted to the FDA.
- Paragraph II: The patent listed has expired.
- Paragraph III: The applicant will not market the generic product before the listed patent expires.
- Paragraph IV: They believe that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
Patent Challenges
A reference product may be protected by multiple patents. It should cover different product aspects. These include active ingredients, formulations, dosage forms, methods of treatment, manufacturing processes, device components, and specific indications.
A generic manufacturer must assess the relevant patents. Then, they should decide if it can wait for expiry, design the claims, challenge the patents, or limit its proposed labeling to exclude protected uses. Patent expiry dates should be verified by product and jurisdiction by jurisdiction.
30-Month Stay
A Paragraph IV certification may lead to patent litigation. If the brand sponsor or patent holder files an infringement action within the applicable 45-day period after receiving notice of the Paragraph IV certification, FDA approval may be postponed for up to 30 months.
This is commonly called a 30-month stay. It is a US-specific mechanism. It does not apply automatically to every patent dispute or to every country. The stay may end before if the patent expires, or a court declares it invalid or not infringed.
Regulatory Exclusivities
Regulatory exclusivity is separate from patent protection. Depending on the product and the applicable law, exclusivity may delay approval or marketing of a competing product even when a particular patent has expired.
New Chemical Entity (NCE) Exclusivity
A drug containing a new active ingredient in the States may receive five years of new chemical entity exclusivity.
Orphan Drug Exclusivity
An eligible orphan drug may receive seven years of US market exclusivity for the approved orphan indication. This exclusivity does not prevent every type of competing product in every circumstance. So, review the specific statutory conditions.
Pediatric Exclusivity
An additional six months of exclusivity may be granted when the sponsor completes qualifying pediatric studies in accordance with the applicable FDA requirements. Pediatric exclusivity generally extends certain existing patent or exclusivity protections rather than creating a completely separate six-month period for every product.
In the European Union, the protection framework is different. For many reference medicines, generic applications may be submitted after eight years of data exclusivity, while marketing is generally protected for ten years, with a possible additional year in certain circumstances.
180-Day Exclusivity for Certain First Generic Applicants
A qualifying first applicant in the US that submits a substantially complete ANDA containing a Paragraph IV certification may be eligible for 180 days of generic drug exclusivity.
This exclusivity is not automatically granted to every first generic applicant. Statutory forfeiture provisions, litigation outcomes, patent expiry, withdrawal of the application, and other factors can affect eligibility.
Labeling Requirements
There should be labeling parity. It means generic drugs must have the same labeling as the brand-name drug, except for any differences that the FDA allows. If this parity is satisfied while also addressing any updates to the brand’s labeling, it can be complex.
Risk Evaluation and Mitigation Strategies (REMS)
If the brand-name drug has an approved REMS, the generic must comply with the same requirements, which can complicate the approval process.
International Regulatory Variations
Regulatory requirements differ between countries. A company planning a multi-market generic launch may need to address different reference-product requirements and local bioequivalence standards. The national labeling rules, patent and exclusivity systems, and import and manufacturing licenses will have different standards everywhere.
The procedure to follow pharmacovigilance obligations, serialization and traceability requirements, local language requirements, substitution and reimbursement rules all vary significantly. For this reason, a generic product approval date in one market does not necessarily indicate when it can be approved or marketed in another.
Don’t let regulatory hurdles slow you down—reach out to Artixio at info@artixio.com today and take the first step towards successful product launches.
Recent Patent Expiries and the Market Dynamics
Several notable drugs have faced patent expiry since 2020. Their prices and market dynamics have been under impact. Here are their examples:
1. Humira (adalimumab) – AbbVie
Patent Expiry: 2023 in the US (Europe – 2018)
Humira is one of the best-selling drugs globally. It faced biosimilar competition in Europe after 2018, leading to many price reductions.
In the US, biosimilars were launched in 2023. Price reductions in the States are not as steep as in Europe due to the complexity of biologics and biosimilar competition. However, Amger and Pfizer-like companies have launched biosimilars. It’ll put downward pressure on Humira’s price.
2. Revlimid (lenalidomide) – Bristol Myers Squibb
Patent Expiry: 2022 in the US
The entry of generic versions of Revlimid in 2022 led to a gradual decrease in its price. As a result, the price impact was less immediate compared to other drugs. Now, as of January 31, 2026, all volume caps have expired. This example illustrates why market entry should be assessed using the relevant patents, settlement terms, approved manufacturers, and distribution restrictions rather than relying on a single patent date.
3. Eliquis (apixaban) – Bristol Myers Squibb and Pfizer
Patent Expiry: Late 2026 (expected)
Eliquis has multiple US patents and exclusivity entries. The FDA’s 2026 Orange Book lists patent information for apixaban products, including a patent expiration date of November 21, 2026. It also has additional patent information extending beyond that date for certain products or protections.
Therefore, November 21, 2026, should not automatically be treated as the date on which all Eliquis products will face unrestricted generic competition. The relevant product, patent claims, litigation outcomes, and regulatory requirements must be reviewed in detail
4. Xarelto (rivaroxaban) – Johnson & Johnson
Patent Expiry: 2024 in the US
Similar to Eliquis, Xarelto is expected to face generic competition soon. The price will likely drop significantly. When generics enter the market, they will make the drug more accessible by cutting into Johnson & Johnson’s revenue.
5. Vimpat (lacosamide) – UCB
Patent Expiry: 2022 in the US
Generic versions of Vimpat were introduced in 2022. They reduced the cost of treatment for epilepsy patients. The market saw significant price drops as multiple generic manufacturers, including Teva and Lupin, launched their versions of the drug.
6. Xtandi (enzalutamide) – Astellas and Pfizer
Patent Expiry: 2027 in the US, 2026 in Europe
Xtandi, used in prostate cancer, is still under patent protection in the US, but it is anticipated that biosimilars and generics will enter the market soon after its patent expires.
7. Gilenya (fingolimod) – Novartis
Patent Expiry: 2022 in the US
The invalidation of Gilenya’s patent opened the door for generic manufacturers to enter the market. It has led to lower prices. Several companies, including HEC Pharma and Biocon, have launched generics.
Conclusion
Drug patent expiry can create opportunities for generic and biosimilar competition. Yet it does not produce the same result for every medicine. Price reductions depend on a lot of factors.
For generic manufacturers, the main challenge is not simply waiting for a patent to expire. It is understanding the complete intellectual-property and regulatory landscape, preparing the appropriate application, managing bioequivalence and quality requirements, and planning market entry on a country-by-country basis.
For innovators, patent expiry requires early preparation, accurate patent monitoring, responsible lifecycle planning, and a clear understanding of how competition may affect pricing, supply, and market access.
Don’t let regulatory hurdles slow you down. Contact Artixio at info@artixio.com for expert consultation and take the next step towards compliance and successful product launches.
